6/12/03

EOI	DM	PTO	L14	140
T. O.		114		~

INFORMATION DISCLOSURE CITATION

Attorney Docket:	Serial No.:	
2458-4042US2	10/019,242	
Applicant:		
DENTON, et al.		
Filing Date:	Group Art Unit:	
December 21, 2001	TBA	

U.S. PATENT DOCUMENTS

Examiner	Patent	Publication				
Initial	Number	Date	Name	Class	Sub-Class	Filing Date
MAG.	5,966,711	10/12/1999	Adams		4	
	6,043,040	03/28/2000	Acton		/	
1	6,030,778	02/29/2000	Acton et al.			
	6,223,128 B1	4/24/2001 .	Allex et al.			
	5,121,320	6/9/1992	Aoki et al.			
	6,222,559 B1	4/24/2001	Asano et al.			
	6,185,561 B1	2/6/2001	Balaban et al.			
	6,081,786	06/27/2000	Barry et al.			
	6,188,988	02/13/2001	Barry et al.			
	5,874,256	02/23/1999	Bertina et al.			
	5,866,404	2/2/1999	Bradshaw et al.			
	6,020,126	2/1/2000	Carlsson et al.			
	6,219,674	04/17/2001	Classen		1	
	5,773,220	06/30/2000	Dekosky et al.			
	5,811,239	09/22/1998	Frayne			
•	5,912,120	06/15/1999	Goldstein et al.			
	5,891,633	04/06/1999	Gonzalez et al.			
	5,297,288	3/22/1994	Hemminger et al.			
	5,762,876	6/9/1998	Lincoln et al.			
	5,811,235	09/22/1998	Jeffreys	-		
	. 5,853,989	12/29/1998	Jeffreys et al.	- 		
1	6,094,626	7/25/2000	Kephart et al.			
	5,361,351	11/1/1994	Lenkov et al.			
	5,953,727	9/14/1999	Maslyn et al.			
	6,189,013 B1	2/13/2001	Maslyn et al.			
	6,175,830 B1	1/16/2001	Maynard			
	5,648,482	07/15/1997	Meyer	<u> </u>		
1	4,706,192	11/10/1987	Nasu et al.			
	6,214,556 B1	4/10/2001	Olek et al.	- - 		
	5,561,754	10/1/1996	Oliver et al.		1	
	5,559,944	9/24/1996	Ono		1 1	
	5,834,183	11/10/1998	Orr et al.		 	
	5,876,933	03/02/1999	Perlin	1		
	5,632,041	5/20/1997	Peterson et al.		1 1	
	6,022,683	02/08/2000	Poirer		 	
	5,862,304	1/19/1999	Ravdin et al.	- - - - 	 	
	6,178,382	01/23/2001	Roederer et al.	- 	 	
	6,141,657	10/31/2000	Rothberg et al.		 \	
	5,972,614	10/26/1999	Ruano et al.	 /	1	
	5,970,500	10/19/1999	Sabatini et al.	 /		
A)	5,966,712	10/12/1999	Sabatini et al.	 /	1	

Examiner	mrs	Date Considered	9/	2le	105	
EXAMINER:	Initial'if reference considered, whether or not citation is in conform	ance with MPEP §609.	$-\tau$			
	Draw line through citation if not in conformance and not considered					
	Include copy of this form with next communication to Applicant.					

FORM PTO-1449 INFORMATION DISCLOSURE CITATION

Attorney Docket:	Serial No.:	
2458-4042US2	10/019,242	
Applicant:		
DENTON, et al.	·	
Filing Date:	Group Art Unit:	
December 21, 2001	TRA	

THYOU	5,972,604	10/26/1999	Santamaria et al		$\overline{}$		" <i>I</i>]	
	5,858,659	01/12/1999	Sapolsky et al.		1			
	5,187,775	2/16/1993	Schroeder et al.					
	5,867,402	2/2/1999	Schneider et al.		TT]	T	
	6,023,659	2/8/2000	Seilhamer et al.	_ 4	T		7	
	5,096,557	03/17/1992	Simons		T		71	
	5,192,659	03/09/1993	Simons		\mathcal{T}^{-}		I = I	
	5,612,179	03/18/1997	Simons		T	1		
	5,789,568	08/04/1998	Simons		$T^{}$			
	5,851,762	12/22/1998	Simons		7	$\top 7$		
1	5,724,253	3/3/1998	Skovira			TT		
1-	5,834,189	11/10/1998	Stevens et al.					
1	5,618,672	4/8/1997	Stodola et al.			17		
17	5,885,776	03/23/1999	Stone et al.	1/		$\top I$		
$\overline{}$	5,502,773	3/26/1996	Tibbetts et al.	1/		\Box		

		FOR	EIGN PATENT DOC	IMENTS		•	
Examiner Initial	Patent Number	Publication Date	Country		Class	Sub-Class	Translation
MNA	WO 87/02802	5/7/1987	PCT				☐ Yes ☐ No
	WO 91/05302	4/18/1991	PCT				☐ Yes ☐ No
	WO 92/01066	1/23/1992	PCT				☐ Yes ☐ No
	WO 95/17524	6/29/1995	PCT				☐ Yes ☐ No
	WO 95/10805	4/20/1995	PCT				Yes No
	WO 97/40462	10/30/1997	PCT				Yes No
	WO 99/05323	02/04/1999	PCT				☐ Yes ☐ No
	WO 99/05324	02/04/1999	PCT				☐ Yes ☐ No
	WO 99/11822	3/11/1999	PCT	· · · · · · · · · · · · · · · · · · ·			☐ Yes ☐ No
 	WO 99/54500	10/28/1999	PCT				☐ Yes ☐ No
	WO 99/57308						☐ Yes ☐ No
	WO 99/64626 ·	12/16/1999	PCT				☐ Yes ☐ No
,//	WO 99/64627	12/16/1999	PCT				☐ Yes ☐ No
V-	WO 00/33161	06/08/2000	PCT				☐ Yes ☐ No
	WO 00/50639A2				· · ·		5, 5,
	(cd format)		PCT				☐ Yes ☐ No
	WO 00/50639A3		~~om	Ť			
	(cd format)		PCT,				Yes No
MAG	WO 01/91026	11/29/2001	PCT				Yes No
4	WO 02/064617	08/22/2002	PCT				Yes No
	EP 0245466B1	5/25/1994	EP				Yes No
	EP 0336560A2	10/11/1989	EP				Yes No
	EP 0336560A3	10/11/1989	EP				Yes No
	EP 0336560B1	11/30/1994	EP				Yes No
/	EP 0404682A2	12/27/1990	EP				Yes No
	EP 0404682B1	12/27/1990	EP				Yes No
Examiner	0000		Date Co	nsidered	0 -1		

Examiner	Mys	Date Considered	9/21/05	
EXAMINER:	Initial if reference considered, whether or not citation is in conform	ance with MPEP §609.		
	Draw line through citation if not in conformance and not considered	i.		
	Include copy of this form with next communication to Applicant.			

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Serial No.:	
10/019,242	
Group Art Unit:	
TBA	•
	10/019,242 Group Art Unit:

WYO	EP 0408188A2	1/16/1991	EP	Yes No
	EP 0408188A3	1/16/1991	EP	Yes No
	EP 0408188B1	1/16/1991	EP	Yes No
	EP 0449494A2	10/2/1991	EP	Yes No
	EP 0449494A3	10/2/1991	EP	Yes No
	EP 0449494B1	8/25/1999	EP	Yes No
	EP 0474944A2	3/18/1992	EP	Yes No
	EP 0474944B1	7/16/1997	EP	Yes No
	EP 0481286A2	4/22/1992	EP	Yes N
	EP 0481286B1	4/9/1997	EP	Yes N
	EP 0494907B1	5/15/1996	EP	Yes N
	EP 0612846A1	8/31/1994	EP	Yes N
	EP 0612846B1	8/16/2000	EP	Yes No
	EP 0673523B1	2/10/1999	EP	Yes N
V	EP 0812922A2	12/17/1997	EP	Yes N

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)
MY	10 4	Beaudet, Arthur L., "1998 ASHG Presidential Address – Making Genomic Medicine a Reality", American Journal of Human Genetics, Vol. 64, pp. 1-13, 1999.
	$\overline{\chi}$	Carter et al., "Genetic Control of Drug-Induced Recovery from Murine Visceral Leishmaniasis", J. Pharm. Pharmacol. 1994, 45:795-798
	4	Cashman, Siobhan M. et al., "The Irish Cystic Fibrosis Database", Journal of Medical Genetics, Vol. 32, pp. 972-975, July 1995.
	-1	Chakraborty, R. "A Class of Population Genetic Questions Formulated as the Generalized Occupancy Problem", Genetics, July 1993, 134:953-958
		Chiano et al. "Fine Genetic Mapping Using Haplotype Analysis and the Missing Data Problem", Ann. Hum. Genet., 1998, 62:55-60.
	2	Clark, Andrew G. et al., "Haplotype Structure and Population Genetic Inferences From Nucleotide-Sequence Variation in Human Lipoprotein Lipase", American Journal of Human Genetics, Vol. 63, pp. 595-612, 1998.
		Clark, Andrew G., "Inference of Haplotypes from PCR-amplified Samples of Diploid Populations", Mol. Biol. Evol., 7(2):111-122, 1990
	-	Cooper, Gillian et al., "Network Analysis of Human Y Microsatellite Haplotypes", Human Molecular Genetics, Vol. 5, Wo. 11, pp. 1759-1766, 1996.
	ا ا	Dempster et al., "Maximum Likelihood from Incomplete Data via the EM Algorithm", J. Statistical Society, Vol. 39, No. 1, pp.1-38, 1977
		Drefus et al. "Etude des Reactions Croisees des Antigenes HLA A et B Chez 63 Patients Atteints de Polyarthrite Rhumatoide", Revue du Rhumatisme, 1984, 51(4), 197-202
		Drysdale, "Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression [\and predict in vivo responsiveness", 2000, Proc. Natl. Acad. Sci. 97(19):10483-8
	ム	Excoffier et al., "Incorporating Genotypes of Relatives into a Test of Linkage Disequilibrium", Am. J. Hum. Genet., 62:171-180, 1998
	1	Excoffier et al. "Maximum-Likelihood Estimation of Molecular Haplotype Frequencies in a Diploid Populations", Mol. Biol. Evol., 1995, 12(5):921-927.
	1/1	Fisher, Lloyd D. et al., "Biostatistics: A Methodology for the Health Sciences", pp. 345-495, 692-762, John Wiley & Sons, Inc.
	V	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket:	Serial No.:	
2458-4042US2	10/019,242	
Applicant:		
DENTON, et al.		
Filing Date:	Group Art Unit:	
December 21, 2001	TBA	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)
Mys	Gene et al., "Haplotype Frequencies of Eight Y-chromosome STR loci in Barcelona (North-East Spain)", International Journal of Legal Medicine, Vol. 112, pp. 403-405, 1999.
	Hartl, Daniel L. et al., "Genetic and Phenotypic Variation", Principles of Population Genetics, pp. 37-109, Singuer Associates, Inc., 3 ed.
	Hawley et al., "HAPLO: A Program Using the EM Algorithm to Estimate the Frequencies of Multi-site Haplotypes", <u>J. of Heredity</u> , 86(5), pp. 409-411, 1995
	-Hill et al., "Human Genetic Variation and Its Impact on Public Health and Medicine", pp.62-74
	Hill, "Tests for Association of Gene Frequencies at Several LOCI in Random Mating Diploid Populations", Biometrics, 31, 881-888, 1975
	Hoang, Liem et al., "PAH Mutation Analysis Consortium Database: A Database for Disease-Producing and Other Allelic Variation at the Human PAH Locus", Nucleic Acids Research, Vol. 24, No. 1, pp. 127-131, 1996.
	Jackson et al., "Pharmacokinetic-Pharmacogenetic Modelling in the Detection of Polymorphisms in Xenobiotic Métabolism", 1990, Ann. Occup. Hyg. 34(6):653-662
·	Judosn et al., "The Predictive Power of Haplotypes in Clinical Response", 2000, pp.1-12
	Judson, Richard, "Genetic Algorithms and Their Use in Chemistry", Reviews in Computational Chemistry, Vol. 10, pp. 1-66, 1997
	Kalow et al., "The Science of Pharmacological Variability: An essay", Clin. Pharma. & Therapeutics, Vol. 66, No. 5, pp.445-447, 1999
	Kardia et al., "An Evolutionary Perspective on the Genetic Architecture of Susceptibility to Cardiovascular Disease", pp. 231-245
	Kleyn, Patrick W. et al., "Genetic Variation as a Guide to Drug Development", Science, Vol. 281, pp. 1820-1821, September 18, 1998.
	Kwok et al., "Single Nucleotide Polymorphism Libraries: Why and How are We Building Them?", Mol. Med. Today, 1999, Vol. 5, pp. 538-543
	Layton et al., "The Therapeutic Response to D-Penicillamine in Rheumatoid Arthritis: Influence of Glutathione S-transferase Polymorphisms", Rheumatology, 1999, 38:43-47
	Long et al., "An E-M Algorithm and Testing Strategy for Multiple-Locus Haplotypes", Am. J. Hum. Genet., 56:799-810, 1995
	MacLean et al., "Estimation of Myriad Haplotype Frequencies", Genetic Epidemiology, 2:263-272, 1985
	Magon, "Pharmacogenetic interactions in G6PD deficiency and development of an in vitro test to predict a drug's hemolytic potential", 1981, Prog. Clin. Biol. Res., 55:709-24
	Matise, T.C., "Genome Scanning for Complex Disease Genes Using the Transmission / Disequilibrium Test and Haplotype-based Haplotype Relative Risk", Genetic Epidemiology, Vol. 12, pp. 641-645, 1995.
	Meyer, Urs A., "Medically Relevant Genetic Variation of Drug Effects", pp. 41-49
	Michalatos-Beloin et al. "Molecular Haplotyping of Genetic Markers 10 kb Apart by Allele-Specific Long Range PCR", Nucleic Acids Research, 1996, 24(23):4841-4843.
	Mori, Motomi et al., "Computer Program to Predict Likelihood of Finding an HLA-Matched Donor: Methodology, Validation, and Application", Biology of Blood and Marrow Transplantation, Vol 2, pp. 134-144, October 1996.
-	Mori, Motomi et al., "HLA Gene and Haplotype Frequencies in the North American Population", Transplantation,. Vol. 64, No. 7, pp. 1017-1027, October 15, 1997.
, , , , , , , , , , , , , , , , , , ,	Neuman et al. "A Bit about Haplotypes: Using Binary Digits to Code Tightly Linked Loci", Hum. Hered., 1994 44:241-247
V.	Niu et al, "Bayesian Haplotype Inference for Multiple Linked Single-Nucleotide Polymorphisms", Am. J. Hum. Genet., 2002, 70:157-169

Examiner	MA	Date Considered	9	Zlo	05	
EXAMINER:	Initial if reference considered, whether or not citation is in conformation line through citation if not in conformance and not considered include copy of this form with next communication to Applicant.			,	,	

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

		6
Attorney Docket:	Serial No.:	
2458-4042US2	10/019,242	
Applicant:		
DENTON, et al.		
Filing Date:	Group Art Unit:	
December 21 2001	TRA	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)
Mila	Olsen et al., "Design and Sample-Size Considerations in the Detection of Linkage Disequilibrium with a Disease Locus", Am. J. Hum. Genet. 1994, 55:574-580
	Perlin, Mark et al., "Toward Fully Automated Genotyping: Allele Assignment, Pedigree Construction, Phase
	Determination, and Recombination Detection in Duchenne Muscular Dystrophy", American Journal of Human Genetics, Vol. 55, pp. 777-787, June 1994.
	Press, William H. et al, "Numerical Recipes in C: The Art of Scientific Computing", pp. 394-455, Cambridge University Press, 2 ed.
	Rich, Elaine et al., "Artificial Intelligence", pp. 514-519, McGraw-Hill, Inc., 2 ed.
	Ruano et al. "Haplotype of Multiple Polymorphisms Resolved by Enzymatic Amplification of Single DNA Molecules", August 1990, Proc. Natl. Acad. Sci., Vol. 87, pp. 6296-6300
	R & D Directions Staff, "Beyond Genomics", R & D Directions, April 1999 pp. 40-44
	Slatkin et al., "Testing for Linkage Disequilibrium in Genotypic Data Using the Expectation-Maximization Algorithm", Heredity, 76:377-383, 1996
	Staessen et al., "M235T Angiotensinogen Gene Polymorphism And Cardiovascular Renal Risk", J. Hypertension, January 1999, 17(1):9-17.
	J.C. Stephens et al., "Haplotype Variation and Linkage Disequilibrium in 313 Human Genes", Science, 2001
	Stephens, J. Claiborne, "Single-nucleotide Polymorphisms, Haplotypes, and Their Relevance to Pharmacogenetics", Molecular Diagnosis, Vol. 4, No. 4, pp. 309-317, December 1999.
	Stephens et al., "A New Statistical Method for Haplotype Reconstruction from Population Data", Am. J. Hum. Genet., 2001, 68:978-989
	Thayer, Ann M., "Bioinformatics for the Masses", C&EN, 19-32, 2000
	Tishkoff S. A. et al., "The Accuracy of Statistical Methods for Estimation of Haplotype Frequencies: An Example from the CD4 Locus", American Journal of Human Genetics, Vol 67, pp. 518-522, August 2000.
	Appleby, "Pharmaceutical Labs Exploring Drugs Tailored to Ethnicity, DNA", January 24, 1999, Las Vegas Review – Journal, Section A, p. 26A.
	Birt, "Drugs Industry Predicted to Be 'Microsoft' For the New Millenium", June 1, 1998, Birmingham Post, pg. 29
	"Bursting with Innovation", December 1997, Med Ad News,
	Craig, "Answers for the Toughest Challenges", April 19, 1999; Forbes, Supplement; Special Advertising Section; Biotechnology, page 2.
-	Debare, "California Spotlight: Incyte plans to conquer DNA mapping within year; Genetics: Part of the plan is to purchase British firm Hexagen for \$41 million", August 23, 1998, The Orange County Register, pg. K01.
	Furuta, "Race to Unlock Genetic Secrets Heats Up in Japan's Laboratories: Analysis of Genes Could Help Create Tatlor-Made Medicines", November 16, 1998, The Nikkei Weekly, pg. 1
	"Genaissance Raises \$10 Million in Private Placement; Accelerates Development of Personalized Medicines Through Pharmacogenomics", August 27, 1998; PR Newswire, Financial News Section
	MacGregor, "Delay is Half The Cure: Nova's Merger With U.S. Firm Steps Up Research Aimed at Postponing Alzheimer's Until It No Longer Matters", March 10, 1999, The Gazette (Montreal), Section D1.
	"Mix/Match Analysis of Gene Diversity in Ethnic Cross-Section Aims at Personalized Medicine", 2001, Bioworld Today, p. 5
	Regalado, "Inventing the Pharmacogenomics Business, Part 1", September 1997, In Vivo the Business & Medicine
	Report, p. 52. Sadee, Wolfgang, "Using Genetic Information to Optimize Drug Therapy", Medscape Pharmacotherapy, 2000
1	"Terrapin and Genaissance Establish Research and Development Collaboration Targeting Drug Candidates Based on
	Estrogen Receptor Modulators Identified in Genomics Research", February 12, 1998, Business Wire

Examiner	\^\^\	Date Considered	1, , , , ,
-	Y Y \ /\ Oth	4/1/2	109
	110190	1/20	
EXAMINER:	Initial if reference considered, whether or not citation is in conform	ance with MPEP §609.	
	Draw line through citation if not in conformance and not considered	d.	
	Include copy of this form with next communication to Applicant.		

Page 6 of 6

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket:	Serial No.:	-
2458-4042US2	10/019,242	
Applicant:		
DENTON, et al.		
Filing Date:	Group Art Unit:	
December 21, 2001	TRA	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)							
The Genesis Group, "Will Pharmocogenomics Create a \$2 Billion Market?", July 1998, Genesis Report, 8(1); pg 26	5;						
"Valigen Acquires Berlin-Based Infogen and Phenotype Database", 2000, Worldwide Biotech							
"Variagenics, Inc. Acquires Exclusive Rights To Leading Pharmacogenomic Technologies for Neurological Disorders", February 8, 1999, Canada Newswire							
Yasuhara, "Ethnic factors in evaluation of drug efficacy and safety", August 1994, Nippon Yakurigaku Zasshi, 102(2): 67-78 (English Abstract)							
Text of April 17, 2001 press release re: Classen patent No. 6,219,674							

Examiner	MOB	Date Considered	9/	261	65	 	
EXAMINER:	Initial if reference considered, whether or not citation is in conformation	ance with MPEP §609.					
	Draw line through citation if not in conformance and not considered	l.					
	Include copy of this form with next communication to Applicant.						

NO.296

JUL 2 7 2004

	Attorney Docket: 2458-4042US2	Senai No.: 10/019,242
FORM PTO-1449	Applicant: DHNTON, et al.	
information disclosure citation	Filing Date: December 21, 2001	Group Art Unit: TBA

5,972,604	10/26/1999	Santamaria et al		<u> </u>	
5,858,659	01/12/1999	Sapolsky et al.	1/		
5,187,775	2/16/1993	Schroeder et al.	1/	 	
5,867,402	2/2/1999	Schneider et al.	4	 	
6,023,659	2/8/2000	Seilhamer et al.	 		
5,096,557	03/17/1992	Simons			
5,192,659	03/09/1993	Simons	 		
5,612,179	03/18/1997	Simons	+	 	
5,789,568	08/04/1998	Simons	 	+	
5,851,762	12/22/1998	Simons			
5,724,253	3/3/1998	Skovira	 	+	
5,834,189	11/10/1998	Stevens et al.			
5,618,672	4/8/1997	Stodola et al.			
5,885,776	· 03/23/1999	Stone et al.			
5,502,773	3/26/1996	Tibbetts et al.			

		EÓR	RIGH BATTENT DOGUNES IS			W. West
Examiner Initial	Patent Number	Publication Date	Country	Class	Sub-Class	Translation
	WO 87/02802	5/7/1987 /	PCT			Yes N
	WO 91/05302	4/18/1991 /	PCT			Yes
	WO 92/01066	1/23/1992/	PCT			Yes N
	WO 95/17524	6/29/1995	PCT	_		Yes D
	WO 95/10805	4/20/1995	PCT			Yes 1
	WO 97/40462	10/30/1997	PCT			
	WO 99/05323	02/04/1999	PCT			
	WO 99/05324	02/94/1999	PCT			
	WO 99/11822	3/1/1999	PCT			☐ Yes ☐ ì
	WO 99/54500	10/28/1999	PCT			Yes 1
	WO 99/57308	/				☐ Yes ☐ 1
	WO 99/64626	12/16/1999	PCT			Yes
	WO 99/64627	12/16/1999	PCT			☐ Yes ☐
	WO 00/33161	06/08/2000	PCT			☐ Yes ☐
-	WO 00/50639A2 (cd format)	0.00,000	PCT			☐Y⇔☐
 -	WO 00/50639A3 (cd format)		PCT			Yes O
	WO 01/91026	11/29/2001	PCT			Yes
	WO 02/064617	08/22/2002	PCT			
	EP 0245466B1	5/25/1994	EP			Yes U
	EP,0336560A2	10/11/1989	RP			
	HP 0336560A3	10/11/1989	EP			Yes
	EP 0336560B1	11/30/1994	EP			
	/EP 0404682A2	12/27/1990	RP			Yes
	/ BP 0404682B1	12/27/1990	EP			

721923 vI

PAGE 23/23 * RCVD AT 7/27/2004 5:45:38 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-2/0 * DNIS:7464050 * CSID: * DURATION (mm-ss):08-20



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18 Stylesheet Version v18.0

> Title of Invention

Methods for Obtaining and Using Haplotype Data

Application Number:

10/019242

Confirmation Number:

4987

First Named Applicant:

Richard Judson Attorney Docket Number: MWH-0032US2

Art Unit:

2857

Search string:

(6537759 or 6664062).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
WA		6537759	2003-03-25	Stanton, Jr.	B1		
	2	6664062	2003-12-16	Stanton, Jr.	B1		·

Signature

Examiner Name	/ Date
1 NVice	9/2le/05

PTO/85/060 (08-03)
Approved for use through 06/30/2005, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it centains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
INFORMATION DISCLOSURE				Application Number	10/019,242	
				Filing Date	12/21/2001	
STATEMENT BY APPLICANT			CANT	First Hamed Inventor	Richard Judson	
				Art Unit	2857	
(Use as many sheets as necessary)				Examiner Name		
8heet	1	cf cf	1	Attorney Docket Number	2458-4042US2	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(a), volume-issue number(a), publisher, city and/or country where published.				
MB	AA	RJ PETERSON ET AL., "Nucleotide sequence diversity in non-coding regions of ALDH2 as revealed by restriction enzyme and SSCP analysis," Human Genetics, Vol. 104 (No. 2), p. 177-87, (February 1999).				
	·					
		·				

Examiner Signature	MVZ	Data Considered	9/26/05

*EXAMINER: Initial if interence considered, whether or not obtation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 97 CPR 1.87 and 1.98. The information is required to obtain or retain a banefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 87 CPR 1.14. This collection is estimated to take 2 haurs to complete.

USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 87 CPR 1.14. This collection is estimated to take 2 haurs to complete. Application form to the USPTO. Time will vary depending upon the IndMetal scase. Any comments on the small regular to the Chief information Officer, U.S. Petant and Tradamark Office, U.S. Department of Commance, P.O. Box 1460, Alexandria, VA 22319-1460. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patants, P.O. Box 1450, Alexandria, VA 22319-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.